Market Closed - Australian S.E. 02:10:20 2024-04-16 am EDT 5-day change 1st Jan Change
0.032 AUD -15.79% Intraday chart for Adherium Limited -20.00% -42.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices MT
Adherium Signs Partnership Deal with Rimidi for Asthma Medication MT
Adherium's Research Collaboration with US Intermountain, CareCentra Enrolls First Patient MT
Adherium Secures AU$1.5 Million R&D Tax Rebate for Fiscal Year 2023 MT
Adherium Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Adherium Appoints CEO MT
Adherium Limited Announces Resignation of Rick Legleiter as Chief Executive Officer CI
Adherium Limited Appoints Lou Panaccio as Executive Chairman of the Board CI
Adherium Limited Announces Change of Company Address CI
Adherium and NuvoAir Medical Forge Partnership for Improved Patient Outcomes MT
Adherium Completes Initial Delivery of Hailie Smart Inhaler Sensors to US Intermountain Health; Shares Jump 6% MT
Adherium Completes 1-for-15 Share Consolidation MT
Adherium Confirms Enrolment of First Patients at SENTA Partners MT
Adherium Launches Next-Generation Respiratory Sensors MT
Adherium Secures First Patients with US Physician Group MT
Adherium Enters Partnership for Rollout of Patient Monitoring Platform in US MT
Adherium Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Adherium Limited Announces Change of Company Address CI
Adherium Signs Deal to Integrate Respiratory Platform with US Partner MT
Adherium Gears Up to Commercialize Monitoring Platform in the US MT
Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary CI
Adherium Limited Announces Executive Changes CI
Adherium Secures US FDA Clearance for Use of Sensor on Teva Inhalers MT
Adherium Limited Receives U.S. FDA 510(k) Clearance for Teva's Proair® and Albuterol Sulphate Inhaler Users to Remotely Monitor Physiological Parameters CI
Adherium Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Chart Adherium Limited
More charts
Adherium Limited is a New Zealand-based international respiratory e-health company. The Company is focused on patient medication adherence, remote monitoring and data management solutions for patients, payers and providers. The Company’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients' use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and chronic obstructive pulmonary disease (COPD), and reduces direct and indirect healthcare costs. The Company’s technologies include The Hailie Remote Patient Management (RPM) Solution, The Hailie Sensors and The Hailie Solution. Its Hailie solution is a cloud-based platform, which captures medication use data from Food and Drug Administration (FDA)-cleared Bluetooth enabled sensors, which wrap around patient inhalers and provide real-time feedback to patients via the Hailie application and to their physicians via the Hailie portal.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ADR Stock
  4. News Adherium Limited
  5. Adherium Secures Healthcare Monitoring Contract in the UK